Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MINK: Methylnaltrexone in Resectable Head and Neck Squamous Cell Carcinoma
NCT06162377Phase 4Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jan 2024
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of methylnaltrexone in oral cavity squamous cell carcinoma (OCSCC), sponsored by University of Texas MD Anderson Cancer Center. Started Jan 2024; status: recruiting.
02
Drugs
methylnaltrexone
03
Conditions
oral cavity squamous cell carcinoma (OCSCC)
Beyond the preview
Go deeper on NCT06162377.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06162377.